We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+50.39%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$3.65B
AUM Growth
+$1.23B
Cap. Flow
+$333M
Cap. Flow %
9.14%
Top 10 Hldgs %
23.51%
Holding
147
New
14
Increased
82
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$36.8M
2
UNH icon
UnitedHealth
UNH
+$30.1M
3
RPRX icon
Royalty Pharma
RPRX
+$24.7M
4
NVAX icon
Novavax
NVAX
+$21.8M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$19.5M

Top Sells

Rank Stock Value
1
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$42.7M
2
ISRG icon
Intuitive Surgical
ISRG
+$17.5M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$6.7M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.68M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.96M

Sector Composition

Rank Sector Weight
1 Healthcare 96.99%
2 Miscellaneous 1.37%
3 Consumer Staples 1.09%
4 Consumer Discretionary 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADPT icon
51
Adaptive Biotechnologies
ADPT
$4.26B
$27.8M 0.76%
575,000
+30,000
+6% +$1.09M
INCY icon
52
Incyte
INCY
$24.7B
$26M 0.71%
250,000
– –
MIRM icon
53
Mirum Pharmaceuticals
MIRM
$6.1B
$25.7M 0.7%
1,319,910
+76,910
+6% +$1.29M
RPRX icon
54
Royalty Pharma
RPRX
$26B
$24.3M 0.67%
+500,000
New +$24.7M
INSP icon
55
Inspire Medical Systems
INSP
$2.16B
$23.1M 0.63%
265,000
+65,000
+33% +$5M
KRTX
56
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$22.7M 0.62%
203,312
+23,312
+13% +$2.03M
ACHC icon
57
Acadia Healthcare
ACHC
$2.55B
$22.6M 0.62%
900,000
– –
TVTX icon
58
Travere Therapeutics
TVTX
$5.89B
$20.9M 0.57%
1,024,261
+449,261
+78% +$7.15M
ALXN
59
DELISTED
Alexion Pharmaceuticals
ALXN
$20.6M 0.56%
+183,500
New +$19.5M
COLL icon
60
Collegium Pharmaceutical
COLL
$711M
$20.6M 0.56%
1,175,000
– –
APRE icon
61
Aprea Therapeutics
APRE
$9.43M
$20.1M 0.55%
25,915
+915
+4% +$600K
ADAP
62
DELISTED
Adaptimmune Therapeutics
ADAP
$19.9M 0.55%
1,986,910
+786,910
+66% +$4.94M
ALLO icon
63
Allogene Therapeutics
ALLO
$594M
$18.9M 0.52%
440,468
+190,468
+76% +$6.89M
HQY icon
64
HealthEquity
HQY
$7.98B
$18.8M 0.52%
320,100
+15,100
+5% +$835K
ODT
65
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$18.5M 0.51%
437,231
+7,231
+2% +$234K
PHR icon
66
Phreesia
PHR
$642M
$18.4M 0.51%
651,500
+86,500
+15% +$2.25M
QURE icon
67
uniQure
QURE
$2.99B
$18.3M 0.5%
407,133
+7,133
+2% +$421K
GBT
68
DELISTED
Global Blood Therapeutics, Inc.
GBT
$18.2M 0.5%
288,279
+8,279
+3% +$568K
TBPH icon
69
Theravance Biopharma
TBPH
$885M
$17.4M 0.48%
828,218
+78,218
+10% +$2.01M
ALLK
70
DELISTED
Allakos
ALLK
$17.2M 0.47%
239,032
+4,032
+2% +$270K
CGEN icon
71
Compugen
CGEN
$228M
$17M 0.47%
1,130,375
+30,375
+3% +$410K
MYOK
72
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$16.7M 0.46%
172,716
+7,716
+5% +$644K
FUSN
73
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$16.4M 0.45%
+937,041
New +$16.3M
ARVN icon
74
Arvinas
ARVN
$540M
$16.1M 0.44%
481,468
+196,468
+69% +$8.34M
WST icon
75
West Pharmaceutical
WST
$25.7B
$16.1M 0.44%
71,000
– –
1 2
3
4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Rock Springs Capital Management held 147 positions worth $3.65B, up 51% from $2.42B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management deployed $333M of net new capital in Q2 2020, opening 14 new positions and adding to 82 existing holdings. Its largest new stake was Royalty Pharma: 500,000 shares worth $24.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Intuitive Surgical, an estimated $17.5M trimmed.

  • Rock Springs Capital Management's largest Q2 2020 buy was Royalty Pharma: 500,000 shares worth $24.3M.
  • Rock Springs Capital Management added most to Centene in Q2 2020, an estimated $36.8M increase.
  • Rock Springs Capital Management's biggest Q2 2020 reduction was Intuitive Surgical, cutting an estimated $17.5M.
  • Rock Springs Capital Management fully exited Forty Seven, Inc. Common Stock in Q2 2020, selling an estimated $42.7M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $3.65B portfolio in Q2 2020.
  • Rock Springs Capital Management opened 14 new positions and closed 4 in Q2 2020.
  • Rock Springs Capital Management's portfolio value rose 51% quarter-over-quarter to $3.65B.

Based on Rock Springs Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.